Refractory Peripheral Primitive Neuroectodermal Tumor: Clinical Trials

3 trials for Refractory Peripheral Primitive Neuroectodermal Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow Refractory Peripheral Primitive Neuroectodermal Tumor: new trials by email Literature Review of Refractory Peripheral Primitive Neuroectodermal Tumor trials Research Report on Refractory Peripheral Primitive Neuroectodermal Tumor

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)202017-11-132026-04-13
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma
Phase 2CompletedNational Cancer Institute (NCI)1082010-11-222021-07-23

Narrower conditions

Medulloblastoma (3)  ·  Neuroectodermal Tumors, Primitive, Peripheral (3)  ·  Central Nervous System Neoplasms (2)  ·  Ependymoma (2)  ·  Glioma (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Neuroblastoma (2)  ·  Osteosarcoma (2)  ·  Rhabdoid Tumor (2)  ·  Rhabdomyosarcoma (2)  ·  Sarcoma (2)  ·  Sarcoma, Ewing (2)  ·  Wilms Tumor (2)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neoplasms, Neuroepithelial (3)  ·  Neuroectodermal Tumors (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genetic Diseases, Inborn (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Histiocytosis (2)  ·  Immune System Diseases (2)

Interventions

Bevacizumab (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Irinotecan (1)  ·  Temozolomide (1)  ·  palbociclib (1)  ·  tazemetostat (1)

Sponsors

National Cancer Institute (NCI) (3)

Countries

Puerto Rico (3)  ·  United States (3)  ·  Australia (1)  ·  Canada (1)  ·  New Zealand (1)

Top investigators

Adam S Levy (1)  ·  Rajen Mody (1)  ·  Susan N Chi (1)

Results publications

PMID 31401903, PMID 39298716

NIH funding

U10CA180886 (3), U10CA098543 (1)